The Pregnancy Test Is Changing.

The Pregnancy Test Is Changing. Here's What It Means for Healthcare Distributors.

On 10 July, BioTeke Corporation received something we have been working toward for over two years: EU IVDR self-testing certification for our Saliva Pregnancy Test Kit, issued under Regulation (EU) 2017/746 by Notified Body CE 3018.

We want to share what this certification means — not just for BioTeke, but for the distributors, importers, and pharmacy partners who are watching the pregnancy diagnostics category transform in real time.

The category is changing. The timing is deliberate.

For decades, the pregnancy test has meant one thing: a urine collection device. The format was clinically effective but inherently undignified — requiring a bathroom, producing contact with bodily waste, and limiting the circumstances under which a woman could test.

The saliva-based pregnancy test changes that entirely. By detecting hCG — the pregnancy hormone — directly in oral fluid, it enables testing anywhere, any time, with nothing more than a collection stick held under the tongue for five seconds.

"A pregnancy test should be as private, dignified, and convenient as the woman using it deserves. We built Saliva Pregnancy Test Kit around that principle — and then we built the clinical and regulatory case to back it up."

 

The global self-testing market alone generates over $240 billion annually and is projected to reach $550 billion by 2030. The pregnancy test segment accounts for approximately $17 billion in 2023. And the IVD market is expanding at 6.1% CAGR, with the particularly strong opportunity for non-invasive diagnostics in women's health. ( The datas only for self test kit, 2023)

$17B+

Pregnancy test market annually

>98%

BIOTEKE SALIVA PREGNANCY TEST sensitivity & specificity

5 min

Time to result from saliva

CE 3018

Notified Body certification

What the IVDR certification process actually required.

Obtaining IVDR self-testing certification is significantly more rigorous than the older IVDD framework. Under Regulation (EU) 2017/746, self-testing devices require a conformity assessment by an EU Notified Body — in our case, CE 3018 — covering:

· Clinical performance evaluation: independent clinical studies demonstrating sensitivity and specificity across a representative population, including pregnant and non-pregnant subjects across all trimesters

· Analytical performance: precision, accuracy, detection limit (≥0.25 mIU/mL hCG in saliva), cross-reactivity panel (LH, FSH, TSH — all confirmed non-reactive)

· Usability evaluation: self-testing devices must demonstrate that a layperson can use the device correctly without professional supervision — including users with low health literacy

· Risk management: comprehensive risk file per ISO 14971

· Post-market surveillance plan: ongoing clinical follow-up commitment post-certification

· Quality Management System: ISO 13485:2016 certification, covering our full manufacturing and quality process

Each of these requirements demanded significant investment in clinical evidence, documentation, and independent validation. We are proud that SaliTest™ passed the full assessment and meets the EU's highest standards for self-testing diagnostics.

What this means for EU importers and distributors.

We supply all authorised distribution partners with a complete compliance documentation package as standard:

· CE Certificate (issued by Notified Body CE 3018)

· Product-specific Declaration of Conformity

· EUDAMED UDI-DI registration confirmation

· Multi-language Instructions for Use (IFU) — mandatory for the global market

· Clinical performance report summary

· ISO 13485:2016 certificate

The distribution opportunity — and why the window is now.

The saliva-based pregnancy test format has already launched for retail — the category is validated and consumer-ready. But the market is not yet crowded. BioTeke is actively seeking authorised distribution partners across the EU and other who want to establish early leadership in this category.

We offer four partnership models:

· Non-exclusive wholesale: open B2B supply with competitive volume pricing tiers and standard MOQ

· Private label / OEM: custom branding available for established pharmacy chains and retail groups

· Co-marketing partnership: joint launch campaigns with BioTeke marketing and regulatory support

"In diagnostics, the distributor who is first in a new category rarely loses their position. The category leadership moment for saliva-based pregnancy testing in Europe is right now — and we want serious partners by our side."

An invitation.

If you are an IVD importer, pharmaceutical wholesaler, pharmacy chain buyer, or clinical distributors - we welcome a direct conversation.

We are ready to dispatch sample kits within 5 business days, provide full regulatory documentation, and discuss partnership terms. Our team will respond to every enquiry within one business day.

Ready to seeking partnership with us? Just contact BioTeke sales team.

Email: zr@bioteke.cn

Phone/Whatsapp: +8613357927939

Website: www.bioteke.cn